Analyst Price Target is $6.75
▲ +25.46% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for Kodiak Sciences in the last 3 months. The average price target is $6.75, with a high forecast of $12.00 and a low forecast of $2.00. The average price target represents a 25.46% upside from the last price of $5.38.
Current Consensus is
The current consensus among 6 investment analysts is to reduce stock in Kodiak Sciences. This Reduce consensus rating has held steady for over two years.
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet biopolymer conjugate for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.